Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-01

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous studies have demonstrated the efficacy of this treatment in certain patients suffering from fecal incontinence, but it is not yet reimbursed in this indication as it is still in the evaluation phase. Indeed, little is known about botulinum toxin mechanisms of action. The aim of this study is to better understand the mechanisms of action of intra-rectal botulinum toxin injections, so that the investigators can identify the patients most likely to benefit from this treatment in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period

NCT01656720

Faecal Incontinence

COMPLETED PHASE2

Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum

NCT00893607

Fecal Incontinence

COMPLETED PHASE1

Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation

NCT01781104

Constipation

COMPLETED PHASE2

Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.

NCT00857467

Fecal Incontinence

COMPLETED PHASE1

Defecation Patterns in Constipated Patients

NCT04903470

Constipation by Outlet Obstruction

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fecal incontinence is a common condition, affecting around 5 to 6% of general population. Although not a serious condition, it severely impairs quality of life and leads to social isolation. Fecal incontinence also has a significant medico-economic cost. When first-line medical treatments fail (transit-regulating therapies, perineal re-education), fecal incontinence patients can be offered treatment with sacral nerve neuromodulation. However, this therapy will only be effective in the long term, and in terms of intention to treat, in less than half of patients who have had the device definitively implanted. Today, no other treatments are available apart from sphincter repair, for which the indications are very limited, or colostomy.

The investigator's team has therefore developed another therapeutic option, intra-rectal injections of botulinum toxin, in patients suffering from active fecal incontinence (i.e., preceded by defecatory urgency). The investigator have conducted two pilot studies, which demonstrated the efficacy of this treatment in an open-label setting, and the investigator are currently completing a randomized, double-blind, controlled study to confirm its efficacy (PHRCN 2014-003650-14). Nevertheless, the mechanisms of action of intra-rectal botulinum toxin injections remain hypothetical. By analogy with the intra-detrusor injections used for over 20 years to treat overactive bladder disease, it is possible that the toxin plays an inhibitory role on rectal motricity. Botulinum toxin inhibits the release of acetylcholine at the neuromuscular junction. Without this release, smooth muscle contraction cannot take place. In one of the two pilot, intra-rectal injections of botulinum toxin were performed in 6 patients with fecal incontinence and hyperactivity of the rectum or colonic reservoir after resection. In addition to the clinically demonstrated effect of these injections, there was a significant reduction in the amplitude of rectal contractions after injection. However, there was no correlation between the observed motor effect of botulinum toxin and the efficacy of the injections. Moreover, some patients did not exhibit colonic or rectal hypermotricity and still benefited from the injections. The investigator would like to continue exploring the motor effect of intra-rectal toxin injections on a larger group of patients suffering from faecal incontinence, using a more powerful motor recording system than anorectal manometry.

For this work, we hypothesize that intra-rectal botulinum toxin injections act primarily via a motor effect by inhibiting propagated rectal contractions. To test this hypothesis, a high-resolution recto-sigmoid manometry probe will be used to evaluate rectal and sigmoidal motricity spontaneously and in response to stimulant laxative injection, before and after intra-rectal injection of botulinum toxin. Patients included will be those suffering from faecal incontinence who have failed conservative treatments and are candidates for intra-rectal injections of botulinum toxin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fecal Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single arm

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intra-rectal botulinum toxin injections

Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.

Group Type EXPERIMENTAL

intra-rectal botulinum toxin injections

Intervention Type DRUG

Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intra-rectal botulinum toxin injections

Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Active or predominantly active fecal incontinence with failure of 1st-line conservative treatments (normalization of transit, perineal re-education)
* Impairment of quality of life at investigator's discretion
* Patients at least 18 years of age
* Patients who have read and understood the information letter and signed the consent form
* Patients affiliated to the French Social Security system
* Women of childbearing age using effective contraception (Cf. CTFG) (estro- progestins or intrauterine device or tubal ligation) for at least 1 month and a negative B-HCG urine pregnancy test at inclusion and for the duration of the study.
* Postmenopausal women: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months prior to inclusion visit)

Exclusion Criteria

General

* Pregnant women, women in labor, breastfeeding women, or women without proven contraception
* Patient deprived of liberty by administrative or judicial decision, or protected adult (under guardianship or trusteeship)
* Exclusive passive fecal incontinence
* Patient suffering from constipation (Rome IV criteria)
* Patient with an evolving inflammatory or cancerous digestive pathology
* Previous rectal surgery
* Person participating in another research protocol or having participated in another research protocol in the 4 weeks preceding the inclusion visit

Linked to botulinum toxin injections

* Hypersensitivity to botulinum toxin or to one of the excipients (human albumin, sodium chloride)
* Neuromuscular junction pathology (myasthenia, Lambert-Eaton syndrome, etc.)
* Presence of infection at injection site(s)
* General anesthesia less than one month ago
* Association with aminoglycosides and anti-cholinesterase agents (risk of increased toxin effects)
* History of neurogenic damage such as polyradiculoneuritis
* History of dysphagia with esophageal or neurological stasis, swallowing disorders, inhalation pneumonitis
* Botulinum toxin injections in the 3 months preceding the study
* Clinical anal examination suggestive of anorectal abscess
* Recent history (\<12 months) of myocardial infarction and/or rhythm disorders not reduced by appropriate treatment
* Peripheral motor neuropathies (such as amyotrophic lateral sclerosis or motor neuropathy) and underlying neurological disorders
* Current treatment with anticoagulants or anti-aggregants or haemostasis disorders according to recommendations (SFED). When patients are on anticoagulant or anti-aggregant therapy, the type of injections to be performed depends on the type of anticoagulation and the patient's thrombo-embolic risk:
* Patients on anticoagulant or anti-aggregant therapy with a major thrombo-embolic risk will not be included.
* Patients on anticoagulant or anti-aggregant therapy with a moderate or low thrombo-embolic risk may be included. If patients are taking a vitamin K antagonist, treatment will be continued provided that the INR is within the usual range of 2 to 3 (GETED, HAS, 2008). If patients are taking anti-aggregants, these can be continued (SFED, HAS, 2012). If patients are taking new oral anticoagulants, they should take a short break and not take the AOD the evening before or the morning of the injections (GIHP, 2015).

Linked to rectosigmoidoscopy

* Local pathology preventing colonoscopy (anal stenosis)
* Allergy or hypersensitivity to silicone and/or latex

Linked to laxatives

* Contraindication to DULCOLAX® 5 mg, gastro-resistant coated tablet
* Contraindication to XIMEPEG®, powder for oral solution

Linked to high-resolution manometry

* Clinically diagnosed intestinal obstruction
* Severe coagulopathy or oral anticoagulants
* Cardiac disorders for which vagal stimulation is poorly tolerated

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No